Hepatitis B Vaccine Facts: Disease Overview, Transmission & Schedule

Overview

Hepatitis B is a liver infection caused by the hepatitis B virus (HBV). It can cause acute illness with symptoms like jaundice, fatigue, and nausea, or become a chronic infection. Chronic HBV affects over 290 million people globally and causes approximately 820,000 deaths annually from liver cancer and cirrhosis (WHO, 2024).

In the United States, about 1.2 million people have chronic hepatitis B. The virus is transmitted through blood, semen, and other body fluids, either sexually or through sharing needles, razors, or other items contaminated with infected blood.

Vaccine and Recommendations

Hepatitis B Vaccine

Type: Recombinant subunit (HBsAg protein)
Schedule: Birth, 1-2 months, 6-18 months (3-dose series)
Efficacy: >90% in healthy adults, nearly 100% in infants
Duration: At least 30 years of protection in most recipients

CDC Recommendations

• Birth dose: Under the January 2026 federal schedule reorganization, the hepatitis B vaccine is now categorized under a dual framework. Tier 2 (High-Risk): The birth dose remains recommended for all infants born to mothers who test HBsAg-positive or whose hepatitis B status is unknown, reflecting the longstanding public health objective of preventing perinatal transmission. Tier 3 (Shared Clinical Decision-Making): For infants born to mothers with confirmed HBsAg-negative status, the hepatitis B vaccine is categorized under shared clinical decision-making, where the decision is based on individual consultation between parents and their healthcare provider. The hepatitis B vaccine remains available and covered by insurance across all tiers.
• All unvaccinated adults at risk should be vaccinated
• People with diabetes, liver disease, or HIV should be vaccinated
• International travelers to endemic regions should be vaccinated

2026 Recommendation Status

2026 Federal Recommendation Status
As of January 5, 2026, hepatitis B vaccination is dually categorized in the federal immunization schedule. It appears in both Tier 2 (recommended for high-risk groups, including infants born to HBsAg-positive mothers) and Tier 3 (Shared Clinical Decision-Making for the general low-risk pediatric population). This dual categorization reflects a risk-stratification approach that differentiates recommendations based on maternal infection status and individual exposure risk. The vaccine, its availability, and insurance coverage remain unchanged.

For the complete three-tier framework, see the Citizen's Guide to the 2026 Schedule Changes.

Standard of Care: Clinical Management

Vaccination remains the most effective strategy for preventing Hepatitis B. The following describes established medical consensus for clinical management.

Clinical Management

Acute Hepatitis B in most adults resolves without treatment — supportive care with rest and hydration is standard. Chronic Hepatitis B requires long-term monitoring of HBV DNA levels, HBsAg status, and liver function. Antiviral therapy with nucleoside/nucleotide analogues (Tenofovir or Entecavir) is recommended for chronic active infection to suppress viral replication, prevent cirrhosis, and reduce risk of hepatocellular carcinoma. Treatment duration is often lifelong. Regular monitoring for liver cancer with ultrasound and AFP is recommended for high-risk patients.

Disclaimer: This information is for educational purposes only. Treatment decisions must be made by a qualified healthcare provider.

Hepatitis B